Summary
7.88 -0.25(-3.08%)07/02/2024
Scholar Rock Holding Corp (SRRK)
Scholar Rock Holding Corp (SRRK)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -3.08 | -3.45 | -14.23 | -51.71 | -53.63 | 9.74 | -47.68 | -47.68 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 7.88 | |
| Open | 8.05 | |
| High | 8.07 | |
| Low | 7.83 | |
| Volume | 47,536 | |
| Change | -0.25 | |
| Change % | -3.08 | |
| Avg Volume (20 Days) | 867,748 | |
| Volume/Avg Volume (20 Days) Ratio | 0.05 | |
| 52 Week Range | 5.93 - 21.17 | |
| Price vs 52 Week High | -62.78% | |
| Price vs 52 Week Low | 32.88% | |
| Range | -2.17 | |
| Gap Up/Down | -0.34 | |
Fundamentals | ||
| Market Capitalization (Mln) | 648 | |
| EBIDTA | -50,847,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 60.60 | |
| Book Value | 5.4120 | |
| Earnings Per Share | -3.4110 | |
| EPS Estimate Current Quarter | -0.8500 | |
| EPS Estimate Next Quarter | -0.7700 | |
| EPS Estimate Current Year | -3.6700 | |
| EPS Estimate Next Year | -4.1700 | |
| Diluted EPS (TTM) | -3.4110 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -6.6286 | |
| Return on asset (TTM) | -0.3266 | |
| Return on equity (TTM) | -0.9787 | |
| Revenue TTM | 18,203,000 | |
| Revenue per share TTM | 0.5070 | |
| Quarterly Revenue Growth (YOY) | 0.7990 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -58,659,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.7058 | |
| Revenue Enterprise Value | 37.8236 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 35,108,100 | |
| Shares Float | 23,899,159 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 3.81 | |
| Institutions (%) | 99.91 | |
06/24 07:00 EST - businesswire.com
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin in.
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the first participants were dosed in the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, an investigational, highly selective myostatin in.
06/18 16:15 EST - businesswire.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 96,700 shares of its common stock to 5 newly hired employees, consisting of inducement stock options to purcha.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 96,700 shares of its common stock to 5 newly hired employees, consisting of inducement stock options to purcha.
06/03 16:00 EST - businesswire.com
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tu.
Scholar Rock Presents New Data from SRK-181 Phase 1 DRAGON Trial at ASCO 2024 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced encouraging data from its Phase 1 DRAGON proof-of-concept trial of SRK-181, a selective inhibitor of latent TGFβ1 activation, in combination with pembrolizumab in patients with advanced solid tu.
05/28 08:00 EST - businesswire.com
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the Ame.
Scholar Rock to Present New Data from SRK-181 Phase 1 DRAGON Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will present new data from its Phase 1 DRAGON proof-of-concept trial of SRK-181 in combination with pembrolizumab in patients with advanced solid tumors in an oral presentation during the Ame.
05/22 07:00 EST - businesswire.com
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the initiation of the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, a highly selective myostatin inhibitor, to preserve lean muscle mass in i.
Scholar Rock Announces Initiation of Phase 2 EMBRAZE Trial of Apitegromab in Obesity and New Preclinical Data Supporting SRK-439 in Obesity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the initiation of the Phase 2 EMBRAZE proof-of-concept trial, designed to assess the safety and efficacy of apitegromab, a highly selective myostatin inhibitor, to preserve lean muscle mass in i.
05/20 08:00 EST - businesswire.com
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in June: UBS Obesity Therapeutics Day: Scholar Rock is scheduled to participate in a virtual fireside chat at 9:00.
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that management will participate in the following upcoming investor conferences in June: UBS Obesity Therapeutics Day: Scholar Rock is scheduled to participate in a virtual fireside chat at 9:00.
05/14 08:00 EST - businesswire.com
Scholar Rock to Host Investor Day on May 22, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City. The Investor Day will feature presentations by members of Scholar Rock's executive management.
Scholar Rock to Host Investor Day on May 22, 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced it will host an Investor Day on Wednesday, May 22, 2024 beginning at 8:30 a.m. ET in New York City. The Investor Day will feature presentations by members of Scholar Rock's executive management.
05/07 07:00 EST - businesswire.com
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2024. “Scholar Rock is now only two quarters away from reporting topline data for our pivotal Phase 3 SAPPHIRE trial,.
Scholar Rock Reports First Quarter 2024 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the first quarter ended March 31, 2024. “Scholar Rock is now only two quarters away from reporting topline data for our pivotal Phase 3 SAPPHIRE trial,.
04/24 06:33 EST - investorplace.com
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.
3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
Investors continue to search for the next big weight loss drug stocks following the success of Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ). So-called GLP-1 receptor agonists represent a fundamental change in weight loss treatment.
03/19 07:00 EST - businesswire.com
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2023. “In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are.
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2023. “In 2023, Scholar Rock made significant progress across our industry-leading antimyostatin pipeline, and we are.
01/25 08:00 EST - businesswire.com
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced a poster presentation at the upcoming Keystone Symposia's Obesity: Causes and Consequences meeting, to be held February 4 – 6, 2024, in Vancouver, BC, Canada. Scholar Rock will present preclinic.
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced a poster presentation at the upcoming Keystone Symposia's Obesity: Causes and Consequences meeting, to be held February 4 – 6, 2024, in Vancouver, BC, Canada. Scholar Rock will present preclinic.
01/23 08:00 EST - businesswire.com
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) (the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 proof-of-concept trial of apitegromab to treat.
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) (the Company), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for its Phase 2 proof-of-concept trial of apitegromab to treat.
01/12 05:32 EST - seekingalpha.com
Scholar Rock: Solid Data And Good Prospects
Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024.
Scholar Rock: Solid Data And Good Prospects
Scholar Rock's stock price has increased from $6 to $16, indicating increased market interest. Scholar Rock develops apitegromab, a targeted therapy for Spinal Muscular Atrophy (SMA) that inhibits myostatin activation. Phase 2 data shows sustained improvement in motor function for non-ambulatory SMA patients receiving apitegromab. Phase 3 data expected in 4Q 2024.
01/02 13:57 EST - investorplace.com
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes you live longer — that perception is pure fiction.
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity's future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes you live longer — that perception is pure fiction.